Prozac pre-patent push
Executive Summary
Lilly will build its U.S. sales force to 2,600 by mid-year to extend promotions of the antidepressant Prozac and the antipsychotic Zyprexa and to initiate launch of Lilly/Takeda's antidiabetic Actos, under review at FDA. Lilly's pipeline includes several new Prozac products: a once-weekly formulation is in Phase III, a combination with Zyprexa is in Phase II, and the company awaits Federal Trade Commission approval of its agreement to license a single-isomer version of fluoxetine from Sepracor (1"The Pink Sheet" March 15, p. 3)
You may also be interested in...
Coty Sees Healing Garden, Calgon As First Prong Of Global Corporate Strategy
Coty, Inc. is looking to globalize its mass market business and stretch its brands into both new product categories and new countries. While historically Coty's global outlook has come about by "accident," it is now the impetus behind the New York City-based firm's new corporate strategy and is transforming the company from a "fast follower" to a "true leader" in the global market, Chair and CEO Peter Harf declared.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials